{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T21:58:17Z","timestamp":1726437497262},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[1998,3,1]],"date-time":"1998-03-01T00:00:00Z","timestamp":888710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T00:00:00Z","timestamp":1419811200000},"content-version":"vor","delay-in-days":6147,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[1998,3]]},"DOI":"10.1111\/j.1469-0691.1998.tb00686.x","type":"journal-article","created":{"date-parts":[[2008,10,27]],"date-time":"2008-10-27T11:20:53Z","timestamp":1225106453000},"page":"S25-S31","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection"],"prefix":"10.1016","volume":"4","author":[{"given":"Sanford","family":"Chodosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0002-9343(85)90361-4","article-title":"Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact","volume":"78","author":"Garibaldi","year":"1985","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib2","article-title":"Medicare and Medicaid statistical supplement, 1995","volume":"16","year":"1995","journal-title":"Health Care Finance Rev"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib3","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archinte.1984.00350190076014","article-title":"Management of pneumonia in the prospective payment era: a need for more clinician and support service interaction","volume":"144","author":"Dans","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0002-9343(85)90364-X","article-title":"Community-acquired lower respiratory tract infections: prevention and cost-control strategies","volume":"78","author":"La Force","year":"1985","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib5","first-page":"263","article-title":"Community-acquired lower respiratory tract infections. the annual cost to the National Health Service","volume":"10","author":"Guest","year":"1996","journal-title":"Br J Med Econ"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0149-2918(97)80050-1","article-title":"Efficacy and safety of grepafloxacin in patients with community-acquired pneumonia","volume":"19","author":"Topkis","year":"1997","journal-title":"Clin Ther"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/40.suppl_1.73","article-title":"Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia","volume":"40","author":"O\u0149Doherty","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib9","series-title":"Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"377","article-title":"Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia. [abstract LM-69]","author":"Patel","year":"1997"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib10","series-title":"Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"377","article-title":"Comparison of grepafloxacin with cefaclor in the treatment of community-acquired pneumonia. [abstract LM-68]","author":"Adams","year":"1997"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/AAC.42.1.114","article-title":"The efficacy and safety of a 10-day course of grepafloxacin 400 mg once daily or 600 mg once daily in the treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of ciprofloxacin 500 mg twice daily","volume":"42","author":"Chodosh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/40.suppl_1.63","article-title":"Randomized double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis","volume":"40","author":"Langan","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/40.suppl_1.27","article-title":"The activity of grepafloxacin against respiratory pathogens in the UK","volume":"40","author":"Wise","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/1120009X.1993.11739245","article-title":"In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers","volume":"5","author":"Sader","year":"1993","journal-title":"J Chemother"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/40.suppl_1.31","article-title":"The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, and Legionella spp","volume":"40","author":"Ridgway","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.1998.tb00686.x_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/j.1875-9114.1996.tb03650.x","article-title":"QT(c)-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: A prospective evaluation and review of the literature","volume":"16","author":"Tschida","year":"1996","journal-title":"Pharmacotherapy"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14650278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14650278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T01:13:36Z","timestamp":1709342016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14650278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":16,"alternative-id":["S1198743X14650278"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.1998.tb00686.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}